SerpApi.Org
President Trump has announced a new tariff plan for imported generic drugs designed to bring production to the United States, which would hopefully lower prices and eliminate some money stress for consumers. However, the generic drug industry is pushing back and pointing out potential issues with the plan that might affect production.
If you or a loved one depend on an imported generic drug, here's what to know about how the plan is supposed to work and what to expect.
The timeline of Trump's generic drug tariff plan
In an effort to shift generic drug production to the United States, Trump has announced a policy that would implement tariffs on imported generic drugs. According to Trump, the tariffs wouldn't go into effect for two years, giving manufacturers the opportunity to transition manufacturing to the U.S.
After two years, tariffs of 100% would be placed on imported generic drugs for one year. At the end of the year, those tariffs would then increase to 200%. The Trump administration reports that the tariffs should help bring pharmaceutical production back to the U.S.
At this time, since tariffs aren't yet implemented, nothing should change at the pharmacy.
Why tariffs for imported generic drugs matter
Generic drugs account for about 90% of U.S. prescriptions, and India supplies nearly half of all of the generic drugs taken in the U.S. These generic medications save U.S. consumers billions in health care costs, and in 2022, the savings from Indian generic drugs alone amounted to $219 billion.
Since generic drug prices are so low, manufacturers of the medications often compete against each other. That fierce competition leaves little room for the manufacturers to absorb any price increases. If tariffs drive up production costs, then drug prices must increase, margins must decrease, or manufacturers might choose not to produce certain products. It's possible that shortages on these medications might occur if a transition to U.S. production lags.
Additionally, building a drug manufacturing system in the U.S. takes at least four to five years, meaning there simply might not be time for manufacturers to transition and implement manufacturing onshore.
How generic drug tariffs might impact the health care system
These tariffs on imported generic drugs could potentially impact the entire health care system. If manufacturers must substantially increase the price of generic drugs because of the cost of bringing production to the U.S., those higher costs might eventually work their way through the greater health care system. Since 90% of generic drugs are imported to the U.S., the tariffs would effectively impact nearly all manufacturers, and the effect of such tariffs could be widespread.
President Trump campaigned on increasing affordability, including reducing drug costs. If the tariffs actually increase the cost of generic drugs, that shift might undermine his campaigning message.
Enjoying our content? Click the Follow button above to see more from us.
The patients who are most at risk because of tariffs on generic drugs
The potential consequences of tariffs on generic drugs put certain patients at risk. An IQVIA study revealed that more than 60% of hypertension and mental health prescriptions in the U.S. are filled with Indian-made drugs, indicating the U.S. is highly dependent on imported generic medications for certain health conditions. Consumers who take medications for such health conditions might feel the impacts of these tariffs the most strongly.
If the tariffs drive up the price of generic medications, then U.S. consumers who are already on tight budgets might be strongly affected. It's possible that some consumers might not be able to afford their medications if prices increase, and they might be forced to go without them. Americans who are enrolled in high-deductible plans may be significantly impacted, as could those who are on Medicare or Medicaid plans.
How Chinese tariffs are affecting U.S. drug production
This isn't the first time that Trump's tariffs have affected medication prices in the U.S. The majority of the raw materials required to manufacture prescription drugs in the U.S. are located outside of the country, and China fulfills about 40% of the global supply of such raw materials. Since Trump took office, tariffs on Chinese imports have increased 20%, driving up the cost of the raw materials that U.S. drugmakers need.
Bottom line
At this time, Trump's tariff plan is an announced policy and is not a settled law. There's already been pushback among manufacturers and industry representatives, and how the tariffs affect manufacturing and prices partially depends on how the administration implements the policy. For example, if the administration only requires manufacturers to demonstrate that efforts are underway to manufacture drugs in the U.S., more manufacturers may be able to meet the two-year timeline and avoid the tariffs.
There's no need to take action now, since the potential effects of the policy are still two years away. As the tariff deadline nears, it may be a good idea to ask your pharmacist about any potential supply disruptions of medications that you take. If price increases are anticipated, give some thought to how you might cope with increasing bills so you're prepared for the cost.
